Study suggests pediatric use of acetaminophen can lead to asthma
LONDON The journal Lancet on Friday announced a large study covering children in 31 countries has found that use of acetaminophen in children in the first year may be at higher risk for developing asthma.
The study consisted of parent-provided reports of 205,000 children and found that acetaminophen use in the first year of life was associated with a 46 percent higher risk of asthma by age six, as compared to children who were not given acetaminophen in the first year.
The findings will be published in the Sept. 20 issue of the journal.
Patent lawsuit over Perrigo’s Monistat-1 dismissed
ALLEGAN, Mich. Perrigo on Thursday announced that the Hatch-Waxman litigation relating to Miconazole Nitrate Vaginal Cream and Suppository between Johnson & Johnson and Perrigo has been dismissed. Accordingly, Perrigo plans to launch a store brand version of the Monistat-1 Combination Pack following Food and Drug Administration approval, the company reported.
“This is another example of Perrigo’s commitment to continue bringing new store brand products to the market, stated Perrigo president and chief executive officer Joe Papa. “The one-day Miconazole cream and suppository introduction to the store brand market provides an important new product in the feminine hygiene category to our retail and wholesale customers while providing significant savings for the consumer. Perrigo is working every day to make quality healthcare more affordable.”
Earlier this year, Perrigo had been sued by Johnson & Johnson’s McNeil unit for infringement of a patent related to Perrigo’s filing of an ANDA for a generic to Monistat-1 Combination Pack in the United States District Court for the District of New Jersey.
Monistat-1 has annual retail sales of approximately $80 million dollars, Perrigo reported. The dismissal of the lawsuit ends the 30 month Hatch-Waxman stay period, which was originally set to expire in September 2010. Perrigo expects its pending launch to have 180 day first-to-file exclusivity.
FullTurn Media’s sexual health survey receives more than 1.2 million responses
NEW YORK FullTurn Media, which hosts the Sexual Health Guru, an online destination for issues of intimate health, on Thursday released a survey that, to date, has generated more than 1.2 million online responses.
“We knew that an anonymous on-line sexual health survey would be a powerful research tool, and we thought that visitors to Sex Health Guru would enjoy participating, but we were still surprised by how quickly it has caught on,” stated Joshua Silberstein, chief executive officer of FullTurn Media.
The research has found, for example, that 27 percent of all female respondents reported taking the emergency contraceptive Plan B at least once, and that 19.1 percent of women under the age of 18 had taken it. FullTurn’s research does not indicate, however, whether those women under the age of 18 had acquired Plan B over-the-counter. Plan B is still a prescription-only medicine for women under the age of 18.